Download PDF
Pharmacopsychiatry 2008; 41(1): 17-23
DOI: 10.1055/s-2007-992148
Original Paper

© Georg Thieme Verlag KG Stuttgart · New York

A Psychoeducational Program for Weight Loss in Patients who have Experienced Weight Gain during Antipsychotic Treatment with Olanzapine

M. Mauri 1 , M. Simoncini 1 , S. Castrogiovanni 1 , N. Iovieno 1 , D. Cecconi 1 , G. Dell'Agnello 2 , M. Quadrigli 2 , A. Rossi 2 , P. Donda 2 , A. Fagiolini 3 , G. B. Cassano 1
  • 1Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Pisa, Italy
  • 2Eli Lilly Italia S.p.A., Sesto Fiorentino (FI), Italy
  • 3Department of Psychiatry, University of Pittsburgh and Department of Neurosciences Division of Psychiatry, University of Siena, Siena, Italy
Further Information

Publication History

received 29.03.2007 revised 17.07.2007

accepted 06.08.2007

Publication Date:
18 January 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Introduction: The aim of this study was to evaluate the efficacy of a psychoeducational program (PEP) for weight control in patients who had experienced an increase of body weight during treatment with olanzapine.

Methods: Eligible patients were randomised to the PEP (Group 1) or to no intervention (Group 2) and continued on olanzapine. After 12 weeks, the PEP was also started in Group 2 and continued in Group 1, up to week 24. Body weight was measured every month. Other measures included quality of life, and change in plasma glucose and lipids levels.

Results: Patients in Group 1 (n=15) had a mean weight loss of 3.6 kg at week 12 and 4.5 kg at week 24 (p<0.01 at both times, p<0.01 between groups at week 12), while those in Group 2 (n=18) had no changes at week 12 and a significant weight loss at week 24 (-3.6 kg from week 12, p<0.01). Changes of BMI paralleled those of body weight. Quality of life (Q-LES-Q-SF categorisation) and functioning (GAF) significantly improved in the total population at endpoint (p<0.01). No significant changes were observed in fasting glucose and lipid profile, while insulin levels significantly decreased from baseline to endpoint in both groups (p<0.05). HOMA index and hepatic insulin sensitivity improved, too.

Discussion: Patients with increased BMI during treatment with olanzapine experienced significant weight and BMI loss following a structured psychoeducational program.

References

  • 1 Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
    PubMedGoogle Scholar
  • 2 American Psychiatric Association. . Releases treatment guideline for bipolar disease.  Am Fam Physician. 1995;  51 1605-1609
    PubMedGoogle Scholar
  • 3 Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain.  Psychiatr Serv. 2001;  52 967-969
    CrossrefPubMedGoogle Scholar
  • 4 Barnes TR. A rating scale for drug-induced akathisia.  Br J Psychiatry. 1989;  154 672-676
    CrossrefPubMedGoogle Scholar
  • 5 Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.  J Clin Psychiatry. 2001;  62 231-238
    CrossrefPubMedGoogle Scholar
  • 6 Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM. et al . Weight loss in overweight patients maintained on atypical antipsychotic agents.  Int J Obes. 2006;  30 1011-1016
    CrossrefPubMedGoogle Scholar
  • 7 Dalle Grave R. Perdere peso senza perdere la testa. In: Riccardo Dalle Grave: Perdere peso senza perdere la testa. Il peso ragionevole in sette passi. Positive Press 2002
    Google Scholar
  • 8 Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.  Psychopharmacol Bull. 1993;  29 321-326
    PubMedGoogle Scholar
  • 9 Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.  Aust N Z J Psychiatry. 2005;  39 479-486
    CrossrefPubMedGoogle Scholar
  • 10 Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute for Mental Health 1976: 218-222
  • 11 Hugenholtz GWK, Heerdink ER, Meijer WE, Stolker J-J, Egberts ACG, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice.  Pharmacopsychiatry. 2005;  38 122-124
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia.  J Clin Psychiatry. 2001;  62 ((Suppl 2)) 41-44
    PubMedGoogle Scholar
  • 13 Kalarchian MA, Marcus MD, Levine MD, Haas GL, Greeno CG, Weissfeld LA. et al . Behavioral treatment of obesity in patients taking antipsychotic medications.  J Clin Psychiatry. 2005;  66 1058-1063
    PubMedGoogle Scholar
  • 14 Keck PE, MacElroy SL. Bipolar disorder, obesity, and pharmacotherapy-associated weight gain.  J Clin Psychiatry. 2003;  64 1426-1435
    CrossrefPubMedGoogle Scholar
  • 15 Khazaal Y, Fresard E, Rabia S, Chatton A, Rothen S, Pomini V. et al . Cognitive behavioural therapy for weight gain associated with antipsychotic drugs.  Schizophr Res. 2007;  91 169-177
    CrossrefPubMedGoogle Scholar
  • 16 Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.  J Clin Psychopharmacol. 2005;  25 255-258
    CrossrefPubMedGoogle Scholar
  • 17 Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus.  Pharmacotherapy. 2002;  22 841-852
    CrossrefPubMedGoogle Scholar
  • 18 Kwon JS, Choi JS, Bahk WM, Yoon Kim C, Hyung Kim C, Chul Shin Y. et al . Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12-week randomized controlled clinical trial.  J Clin Psychiatry. 2006;  67 547-553
    PubMedGoogle Scholar
  • 19 Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, MacEvoy JP. et al . Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.  Am J Psychiatry. 2003;  160 290-296
    CrossrefPubMedGoogle Scholar
  • 20 Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnsson CG. The effects of and educational intervention of antipsychotic-induced weight gain.  J Nurs Scholarsh. 2003;  35 237-241
    CrossrefPubMedGoogle Scholar
  • 21 Matthews DR, Hosker JP, Rudenski AS, Taylor BA, Treacher DF, Turner R. Homeostasis model assessment insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
    Google Scholar
  • 22 McIntyre RS, MacCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities.  Can J Psychiatry. 2001;  46 273-281
    PubMedGoogle Scholar
  • 23 Mithat B, Alpaslan T, Bulent C, Cengiz T. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium.  Pharmacopsychiatry. 2005;  38 105-106
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Muench J, Carey M. Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.  J Am Board Fam Pract. 2001;  14 278-282
    PubMedGoogle Scholar
  • 25 Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.  CNS Drugs. 2005;  19 ((Suppl 1)) 1-93
    CrossrefPubMedGoogle Scholar
  • 26 Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.  J Affect Disord. 2002;  70 19-26
    PubMedGoogle Scholar
  • 27 Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.  Lancet. 2002;  359 2086-2087
    CrossrefPubMedGoogle Scholar
  • 28 Scocco P, Longo R, Caon F. Weight change in treatment with olanzapine and a psychoeducational approach.  Eat Behav. 2006;  7 115-124
    CrossrefPubMedGoogle Scholar
  • 29 Sharma R, Markar HR. Mortality in affective disorder.  J Affect Disord. 1994;  31 91-96
    PubMedGoogle Scholar
  • 30 Sowell MO, Mukhopadhyay N, Cavazzoni P, Carlson C, Mudaliar S, Chinnapongse S. et al . Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.  J Clin Endocrinol Metab. 2003;  88 5875-5880
    CrossrefPubMedGoogle Scholar
  • 31 Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A. et al . Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.  J Clin Endocrinol Metab. 2002;  87 2918-2923
    CrossrefPubMedGoogle Scholar
  • 32 Sussman N. The implications of weight changes with antipsychotic treatment.  J Clin Psychopharmacol. 2003;  23 ((Suppl 1)) S21-26
    CrossrefPubMedGoogle Scholar
  • 33 Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.  J Clin Psychiatry. 1997;  58 205-211
    PubMedGoogle Scholar
  • 34 Turner RC, Holman RR, Matthews D, Hockaday TD, Peto J. Insulin deficiency and insulin resistance interaction in diabetes: estimation of their relative contribution by feedback analysis from basal plasma insulin and glucose concentrations.  Metabolism. 1979;  28 1086-1096
    CrossrefPubMedGoogle Scholar
  • 35 United States Department of Agriculture and United States Department of Health and Human Services .Dietary Guidelines for Americans 2000, Home and Garden Bulletin No. 232, 5th edn. 2000. U.S. Government Printing Office Washington, DC
  • 36 Wetterling T. Bodyweight gain with atypical antipsychotics.  A comparative review. Drug Saf. 2001;  24 59-73
    PubMedGoogle Scholar
  • 37 Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.  J Clin Psychiatry. 2002;  63 1148-1155
    CrossrefPubMedGoogle Scholar
  • 38 Zhang XY, Tan YL, Zhou DF, Haile CN, Cao LY, Xu Q. et al . Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population.  J Clin Psychopharmacol. 2007;  27 246-251
    CrossrefPubMedGoogle Scholar

Correspondence

M. MauriMD 

Department of Psychiatry

School of Medicine

University of Pisa

Via Roma 67

56100 Pisa

Italy

Phone: +39/050/835 410

Fax: +39/050/21 581

Email: mmauri@med.unipi.it

      >